- Design
- Phase 2, randomised, controlled trial (terminated early)
- Population
- 98 patients with limited-stage small-cell lung cancer after chemoradiotherapy
- Primary outcome
- Progression-free survival
- Effect
- PFS HR 0.55 (0.31-0.96); OS HR 0.39 (0.19-0.80); grade 3 pneumonitis about 4%
A phase 2 randomised trial assigned 98 patients with limited-stage small-cell lung cancer who had completed concurrent chemoradiotherapy to six months of consolidation toripalimab (a PD-1 inhibitor) or observation, with progression-free survival as the primary endpoint.
Progression-free survival was not reached with toripalimab versus 14.1 months with observation (hazard ratio 0.55, 95% CI 0.31-0.96), and overall survival also favoured toripalimab (median not reached vs 30.3 months; hazard ratio 0.39, 0.19-0.80), with benefit consistent across subgroups. Toxicity was generally mild, with grade 3 pneumonitis in about 4%.
This extends the consolidation-immunotherapy approach, already established in extensive-stage disease, to limited-stage small-cell lung cancer, where options are few. But it is a small phase 2 trial stopped early, which tends to overstate effect sizes, so it is a strong signal to confirm in adequately powered trials rather than a settled standard.
- Consolidation toripalimab after chemoradiotherapy improved progression-free survival (hazard ratio 0.55).
- Overall survival also favoured toripalimab (hazard ratio 0.39).
- Benefit was consistent across predefined subgroups.
- Toxicity was mostly mild, with grade 3 pneumonitis in about 4%.
- It is a small phase 2 trial stopped early, so confirmation is needed.
Why it matters
It raises the prospect of extending a proven extensive-stage strategy to limited-stage disease, where little has changed.
Don't overread it
Small phase 2 trial terminated early; effect estimates are likely optimistic and require confirmation before practice change.
The statistics, in plain English
Hazard ratios of 0.55 and 0.39 suggest large reductions in progression and death, but a small trial halted early can exaggerate benefit, and the wide confidence intervals reflect that uncertainty.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for pulmonology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free